INTU
56
-4
VRSN
53
-4
URI
65
5
LNC
39
3
SLB
55
2
AXP
71
2
FITB
63
3
INTC
33
-2
TGT
22
2
DHI
48
4
BK
74
2
MPC
44
-3
BWA
48
2
HCA
44
-2
ACN
52
3
LMT
34
2
FDX
43
3
NDAQ
62
2
M
37
12
WDC
47
4
INTU
56
-4
VRSN
53
-4
URI
65
5
LNC
39
3
SLB
55
2
AXP
71
2
FITB
63
3
INTC
33
-2
TGT
22
2
DHI
48
4
BK
74
2
MPC
44
-3
BWA
48
2
HCA
44
-2
ACN
52
3
LMT
34
2
FDX
43
3
NDAQ
62
2
M
37
12
WDC
47
4
Financhill
Back

Haemonetics 10K Form

Buy
72

HAE
Haemonetics

Last Price:
85.59
Seasonality Move:
0.66%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-02-08 10Q HAE/Haemonetics Quarterly
2023-11-02 10Q HAE/Haemonetics Quarterly
2023-08-08 10Q HAE/Haemonetics Quarterly
2023-02-07 10Q HAE/Haemonetics Quarterly
2022-11-08 10Q HAE/Haemonetics Quarterly
2022-08-10 10Q HAE/Haemonetics Quarterly

Receive HAE News And Ratings

See the #1 stock for the next 7 days that we like better than HAE

HAE Financial Statistics

Sales & Book Value

Annual Sales: $1.31B
Cash Flow: $39.39M
Price / Cash Flow: 216.12
Annual Sales: $17.44
Price / Book: 4.89

Profitability

EPS (TTM): 2.41000
Net Income (TTM): $123.81M
Gross Margin: $691.55M
Return on Equity: 13.51%
Return on Assets: 5.4%

Haemonetics Earnings Forecast

Key Haemonetics Financial Ratios

  • The Gross Profit Margin over the past 33 years for HAE is 52.83%.
  • The Selling, General & Administrative Expenses for HAE have been equal to 32.98% of Gross Profit Margin.
  • The Research & Development expenses have been 4.16% of Revenue.
  • The Interest Expense is 11.07% of Operating Income.
  • The Net Earning history of HAE is 8.98% of Total Revenues.
  • Per Share Earnings over the last 34 years have been positive in 21 years.

Haemonetics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: HAE
CUSIP: 405024
Website: haemonetics.com

Debt

Debt-to-Equity Ratio: 1.39
Current Ratio: 3.49
Quick Ratio: 1.87

Price-to-Earnings

Trailing P/E Ratio: 37.36
Forward P/E Ratio: 15.98

HAE Technical Analysis vs Fundamental Analysis

Buy
72
Haemonetics (HAE) is a Buy

Is Haemonetics a Buy or a Sell?

  • Haemonetics stock is rated a Buy
    The current Haemonetics [HAE] share price is $85.55. The Score for HAE is 72, which is 44% above its historic median score of 50, and infers lower risk than normal.